Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Delaware Health News Online.
Press releases published on August 7, 2025
Microbix Schedules Release of Results for Q3 Fiscal 2025 Results Release and Webinar Discussion on Morning of August 14, 2025
GlobeNewswire
·
August 7, 2025
MISSISSAUGA, Ontario, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure …
FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes
GlobeNewswire
·
August 7, 2025
FibroGen has reached agreement with the FDA on important design elements for a pivotal Phase 3 clinical trial for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high red blood cell (RBC) …
Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 7, 2025
‒ Q2 2025 Net Revenue of $39.7mm; Net Income of $19.8mm; Adjusted EBITDA of $22.4mm ‒ ‒ Company Announces Acquisition of Melinta Therapeutics ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., Aug. 07, 2025 (GLOBE …
HUTCHMED Reports 2025 Interim Results
GlobeNewswire
·
August 7, 2025
— Indications expansion driving growth and ATTC platform enriching pipeline — — $455 million in net income attributable to HUTCHMED driven by non-core partial disposal — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- …
XORTX Provides Corporate Update and Planned Activities for 2025 / 2026
GlobeNewswire
·
August 7, 2025
CALGARY, Alberta, Aug. 07, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …
CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings
GlobeNewswire
·
August 7, 2025
Transformational deal for CorMedix that expands and diversifies company’s commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential Transaction expected to be near-term …
Verano Announces Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
CHICAGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced its financial results for the second quarter ended June 30, 2025, which …
GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
August 7, 2025
Global pivotal program initiation on track for 2026 Engagement with FDA on GH001 IND complete response ongoing The fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no psychotherapy …
Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 7, 2025
- Positive Clinical Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Confirm Tolerability Profile, Show Strong Efficacy Signal, and Validate ITK as Therapeutic Target - - Advanced Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) into Phase 2 …
Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
August 7, 2025
Over 580,000 VOQUEZNA® prescriptions filled to date, reflecting 49% growth since last earnings report Net revenues of $39.5 million reported for Q2 Full-year 2025 revenue guidance of $165 million to $175 million Company remains focused on path to …
Aveanna Healthcare Holdings Announces Second Quarter Financial Results and Revised 2025 Outlook
GlobeNewswire
·
August 7, 2025
Second Quarter Revenue was $589.6 million, a 16.8% increase over the prior year period Second Quarter Net income was $27.0 million, a 94.3% increase over the prior year period Adjusted EBITDA for Q2 2025 was $88.4 million, a 93.6% increase over the prior …
Privia Health Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
Very Strong First Half Performance Across All Key Operating and Financial Metrics Implemented Providers +13.8% and Practice Collections +18.5% compared to 2Q’24 Guidance Raised to Above High End of Range for Practice Collections, GAAP Revenue, Platform …
Dentsply Sirona Reports Second Quarter 2025 Results
GlobeNewswire
·
August 7, 2025
Net sales of $936 million decreased (4.9%), decreased (6.7%) in constant currency including a (3.2%) Byte sales impact GAAP gross margin of 52.4%, GAAP net loss per share of ($0.22) Adjusted gross margin of 55.9%, adjusted EBITDA margin of 21.1%, adjusted …
Enovis Announces Second Quarter 2025 Results
GlobeNewswire
·
August 7, 2025
Continued commercial momentum with second-quarter sales growth of 7% on a reported basis Second-quarter Reconstructive sales grew 11% year-over-year on a reported basis Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “ …
LifeStance Reports Second Quarter 2025 Results
GlobeNewswire
·
August 7, 2025
SCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the second quarter ended June 30, 2025. (All …
DeepHealth, a RadNet Subsidiary, Receives FDA Clearance for Remote Scanning Solution, TechLive™
GlobeNewswire
·
August 7, 2025
TechLive™ is a vendor-agnostic integrated solution enabling remote scanning of MR, CT, PET/CT, and Ultrasound procedures Amidst radiology technologist shortages, remote scanning in a command center configuration enables the workforce to scan at multiple …
Accumulus Synergy gliedert Accumulus Technologies aus, um bewährte Regulierungsplattform zu skalieren und den globalen Zugang zu Therapien zu beschleunigen
GlobeNewswire
·
August 7, 2025
BURLINGAME, Kalifornien, Aug. 07, 2025 (GLOBE NEWSWIRE) -- In einem richtungsweisenden Schritt zur Förderung regulatorischer Innovationen und zur besseren Deckung der weltweit steigenden Nachfrage hat Accumulus Synergy, ein gemeinnütziger Branchenverband, …
Accumulus Synergy crée Accumulus Technologies pour développer sa plateforme réglementaire éprouvée et accélérer l’accès mondial aux thérapies
GlobeNewswire
·
August 7, 2025
BURLINGAME, Californie, 07 août 2025 (GLOBE NEWSWIRE) -- Dans une démarche audacieuse visant à accélérer l’innovation réglementaire et à répondre à la demande mondiale croissante, Accumulus Synergy, une association professionnelle à but non lucratif, a …
アキュミュラスシナジー (Accumulus Synergy)、実績ある規制プラットフォームを拡大し、治療への世界的なアクセスを加速させるため、アキュミュラステクノロジーズ (Accumulus Technologies)…
GlobeNewswire
·
August 7, 2025
カリフォルニア州バーリンゲーム発, Aug. 07, 2025 (GLOBE NEWSWIRE) -- 規制のイノベーションを迅速化し、拡大する世界的な需要に対応するための大胆な施策として、非営利の業界団体であるアキュミュラスシナジーは本日、アキュミュラスプラットフォーム (「プラットフォーム」) の拡大と進化を目的に設立された新たな商業技術企業、アキュミュラステクノロジーズの創設を発表した。同プラットフォームは、アキュミュラスシナジー内でインキュベートされ、2024 …
SNIPR BIOME Raises EUR 35 Million Series B Financing to Advance CRISPR-Medicines Targeting Antimicrobial Resistance
GlobeNewswire
·
August 7, 2025
COPENHAGEN, Denmark, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SNIPR Biome ApS (“SNIPR”), the company pioneering the development of microbial CRISPR-medicine, today announced the close of a EUR 35 million Series B raise with funding from new investors the Cystic …